Barclays PLC Boosts Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Barclays PLC raised its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 145.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 79,740 shares of the company’s stock after acquiring an additional 47,239 shares during the period. Barclays PLC’s holdings in Stoke Therapeutics were worth $980,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Quest Partners LLC bought a new stake in Stoke Therapeutics in the second quarter worth about $29,000. Intech Investment Management LLC purchased a new position in Stoke Therapeutics during the 3rd quarter valued at $160,000. The Manufacturers Life Insurance Company grew its holdings in shares of Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after purchasing an additional 1,994 shares during the last quarter. Mesirow Financial Investment Management Inc. purchased a new position in shares of Stoke Therapeutics during the third quarter worth approximately $192,000. Finally, Profund Advisors LLC purchased a new position in Stoke Therapeutics during the 2nd quarter worth $201,000.

Insider Buying and Selling

In other news, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the sale, the insider now owns 51,277 shares in the company, valued at $618,913.39. This represents a 16.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Edward M. Md Kaye sold 6,170 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $78,852.60. Following the sale, the chief executive officer now directly owns 68,671 shares in the company, valued at $877,615.38. The trade was a 8.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,849 shares of company stock valued at $809,421 over the last 90 days. Insiders own 11.30% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on STOK. Leerink Partners started coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, January 8th. Chardan Capital assumed coverage on Stoke Therapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $24.00 price target on the stock. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $21.29.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $8.68 on Wednesday. The stock has a 50-day moving average of $11.73 and a two-hundred day moving average of $12.97. The stock has a market cap of $459.75 million, a P/E ratio of -4.13 and a beta of 0.95. Stoke Therapeutics, Inc. has a one year low of $4.09 and a one year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Analysts predict that Stoke Therapeutics, Inc. will post -2.03 EPS for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.